SI2949658T1 - Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe - Google Patents

Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe

Info

Publication number
SI2949658T1
SI2949658T1 SI200432448T SI200432448T SI2949658T1 SI 2949658 T1 SI2949658 T1 SI 2949658T1 SI 200432448 T SI200432448 T SI 200432448T SI 200432448 T SI200432448 T SI 200432448T SI 2949658 T1 SI2949658 T1 SI 2949658T1
Authority
SI
Slovenia
Prior art keywords
cmet
peptides
specifically bind
hgf receptor
bind hgf
Prior art date
Application number
SI200432448T
Other languages
English (en)
Slovenian (sl)
Inventor
Aaron K. Sato
Daniel T. Dransfield
Robert C. Ladner
Original Assignee
Dyax Corp.
Bracco Suisse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp., Bracco Suisse Sa filed Critical Dyax Corp.
Publication of SI2949658T1 publication Critical patent/SI2949658T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicinal Preparation (AREA)
SI200432448T 2003-03-03 2004-03-03 Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe SI2949658T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45158803P 2003-03-03 2003-03-03
EP15157779.8A EP2949658B1 (en) 2003-03-03 2004-03-03 Peptides that specifically bind HGF receptor (cMet) and uses thereof

Publications (1)

Publication Number Publication Date
SI2949658T1 true SI2949658T1 (sl) 2018-10-30

Family

ID=32962606

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432448T SI2949658T1 (sl) 2003-03-03 2004-03-03 Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe

Country Status (13)

Country Link
US (6) US20050214859A1 (cg-RX-API-DMAC7.html)
EP (4) EP1944312B1 (cg-RX-API-DMAC7.html)
JP (4) JP5466350B2 (cg-RX-API-DMAC7.html)
AU (2) AU2004217894B2 (cg-RX-API-DMAC7.html)
CA (1) CA2517939C (cg-RX-API-DMAC7.html)
CY (1) CY1120683T1 (cg-RX-API-DMAC7.html)
DK (2) DK2949658T3 (cg-RX-API-DMAC7.html)
ES (3) ES2692166T3 (cg-RX-API-DMAC7.html)
HU (1) HUE039154T2 (cg-RX-API-DMAC7.html)
PL (2) PL2949658T3 (cg-RX-API-DMAC7.html)
PT (1) PT2949658T (cg-RX-API-DMAC7.html)
SI (1) SI2949658T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004078778A2 (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
SI2949658T1 (sl) * 2003-03-03 2018-10-30 Dyax Corp. Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
JP2008516629A (ja) * 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
US8236761B2 (en) 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
EP2114427B1 (en) * 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
WO2008139207A2 (en) * 2007-05-16 2008-11-20 Ge Healthcare As Labelled hgf binding peptides for imaging
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
CA2779730C (en) 2009-11-05 2019-04-30 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
US9393177B2 (en) 2013-08-20 2016-07-19 Anutra Medical, Inc. Cassette assembly for syringe fill system
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
HK1226308A1 (zh) 2013-08-30 2017-09-29 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
BR112016010166A2 (pt) 2013-11-11 2017-12-05 Armo Biosciences Inc métodos para usar interleucina-10 para tratar doenças e distúrbios
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2016023895A1 (en) * 2014-08-11 2016-02-18 Miti Biosystems GmbH Cyclic peptides expressed by a genetic package
WO2016049044A1 (en) * 2014-09-22 2016-03-31 National Health Research Institutes Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
CA2963989A1 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
CA2986774A1 (en) 2015-05-29 2016-12-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
DK3307296T3 (da) 2015-06-15 2021-12-13 Univ Leland Stanford Junior Timp2 til anvendelse til behandling af aldringsassocierede tilstande
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
SMT202200173T1 (it) * 2016-06-01 2022-05-12 Athira Pharma Inc Composti
WO2018022603A1 (en) 2016-07-25 2018-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
EP3514167B1 (en) * 2016-09-13 2022-04-13 Daiichi Sankyo Company, Limited Thrombospondin 1-binding peptide
US11739163B2 (en) 2016-09-29 2023-08-29 Aebi Ltd. Therapeutic multi-targeting constructs and uses thereof
BR112019006802A2 (pt) 2016-10-07 2019-07-09 Navidea Biopharmaceuticals Inc compostos e métodos para diagnóstico e tratamento de infecções virais
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
BR112021025124A2 (pt) * 2019-06-14 2022-01-25 Edinburgh Molecular Imaging Ltd Composto, composição farmacêutica, kit para a preparação da composição farmacêutica, métodos de imagiologia e radioterapia do corpo de mamífero, de detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia e de obtenção de uma imagiologia de locais e/ou tratamento de condições associadas à superexpressão ou localização de cmet in vivo, e, uso
IL292863A (en) 2019-11-13 2022-07-01 Amunix Pharmaceuticals Inc Barcoded xanthan polypeptides and their compositions, and methods for their preparation and use
TW202305012A (zh) * 2021-03-22 2023-02-01 日商肽夢想股份有限公司 c-Met 蛋白質結合肽複合物
JP7162853B1 (ja) 2021-07-02 2022-10-31 ペプチスター株式会社 液相ペプチド合成用担体結合ペプチドの分析方法
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
JP2025517414A (ja) 2022-05-20 2025-06-05 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 分解性リンカーを介して新規ビスホスホネート薬物ペイロードを担持するｃｄ２０６標的化薬物送達ビヒクル

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3834705A1 (de) 1988-10-07 1990-04-12 Schering Ag Ultraschallkontrastmittel aus gasblaeschen und fettsaeure enthaltenden mikropartikeln
DE3313946A1 (de) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
DE3313947A1 (de) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
ATE173336T1 (de) 1989-08-28 1998-11-15 Gen Hospital Corp Hydroxy-aryl metallchelate für bildformung zur nmr diagnose
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
CA2034042C (en) 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (cg-RX-API-DMAC7.html) 1990-04-02 1993-05-01 Sint Sa
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5173298A (en) 1990-09-27 1992-12-22 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
JP2774378B2 (ja) 1991-02-08 1998-07-09 ダイアテク，インコーポレイテッド 映像用テクネチウム−９９ｍ標識化ポリペプチド
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5849261A (en) 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
EP0536350B1 (en) 1991-02-22 2002-08-07 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5558857A (en) 1991-06-03 1996-09-24 Nycomed Imaging As Contrast agents
WO1993000930A1 (en) 1991-07-05 1993-01-21 Holmes, Michael, John Improvements in or relating to contrast agents
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
ATE222603T1 (de) * 1992-05-18 2002-09-15 Genentech Inc Hepatozytwachstumfaktor variante
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
JPH08500246A (ja) * 1992-08-10 1996-01-16 ケンブリッジ ニューロサイエンス インコーポレーテッド 細胞増殖の阻害剤，その調製および用途
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
BR9406993A (pt) 1993-07-02 1996-09-10 Molecular Biosystems Inc Microesferas de gases insolúveis encapsulados com proteína e sua preparação e uso como agentes de imagem ultrassônica
AU7261994A (en) 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
JPH10508284A (ja) 1993-12-15 1998-08-18 ブラッコ リサーチ ソシエテ アノニム 超音波造影媒体、この媒体を含む造影剤及び方法
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
DE69434538T2 (de) 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vaskulärer endothelialer Wachstumsfaktor 2
JP2891647B2 (ja) 1994-03-11 1999-05-17 株式会社日本触媒 有機スルフィド化合物及びその製造方法
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
CA2188292A1 (en) 1994-04-20 1995-11-02 Larry Margerum Contrast agents
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5556939A (en) 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
TW319763B (cg-RX-API-DMAC7.html) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
ATE265863T1 (de) 1995-06-07 2004-05-15 Imarx Pharmaceutical Corp Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6451764B1 (en) 1995-09-08 2002-09-17 Genentech, Inc. VEGF-related protein
AU1116297A (en) 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
US5837680A (en) 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
PT881915E (pt) 1996-02-19 2003-09-30 Amersham Health As Melhorias em ou relativas a agentes de contraste
IL125895A (en) 1996-04-01 2001-09-13 Epix Medical Inc Use of an image-enhancing moiety in the preparation of a bioactivated nmr or optical imaging contrast agent from a prodrug
MXPA99001053A (es) 1996-08-02 2002-03-11 Nycomed Imaging As Mejoramientos en o que se relacionan con agentes de contraste.
TW320761B (en) * 1996-10-03 1997-11-21 Mos Electronics Taiwan Inc Manufacturing method of high density DRAM with cylindrical stack capacitor
CA2269319C (en) 1996-10-21 2008-03-18 Nycomed Imaging As Improvements in or relating to contrast agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
EP0946202B1 (en) 1996-10-28 2003-09-10 Amersham Health AS Contrast agents
EP0991427A2 (en) 1996-10-28 2000-04-12 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
ES2264159T3 (es) 1996-10-28 2006-12-16 Amersham Health As Mejoras en/o relacionadas con agentes de diagnostico/terapeuticos.
WO1998018496A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
KR20000052829A (ko) 1996-10-28 2000-08-25 조오지 디빈센조, 토브 아스 헬지, 에바 요한손 진단/치료제 또는 그와 관련된 개선
EP0963209A2 (en) 1996-10-28 1999-12-15 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
EP1009814B1 (en) 1997-06-18 2007-08-29 Merck & Co., Inc. (a New Jersey corp.) Human receptor tyrosine kinase, kdr
HUP0101245A3 (en) 1997-10-02 2003-10-28 Epix Pharmaceuticals Inc Cambr Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
WO1999030157A2 (en) 1997-12-09 1999-06-17 Children's Medical Center Corporation Neuropilins in methods for diagnosis and prognosis of cancer
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
DE69925461T2 (de) 1998-02-09 2006-04-27 Bracco International B.V. Zielgerichtete abgabe von biologische-aktive medien
EP1056773A2 (en) 1998-02-11 2000-12-06 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
CA2324555A1 (en) 1998-03-31 1999-11-18 Du Pont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
ID29063A (id) 1998-11-06 2001-07-26 Basf Ag Penghambatan formasi dari hiperpermeabilitas vaskular
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
JP2002542766A (ja) * 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
JP2002542767A (ja) * 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４７個のヒト分泌タンパク質
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9928950D0 (en) 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
WO2001052875A1 (en) 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Vegf-d/vegf-c/vegf peptidomimetic inhibitor
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2001057067A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
WO2001062942A2 (en) 2000-02-25 2001-08-30 Ludwig Institute For Cancer Research MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
KR20020080461A (ko) 2000-03-02 2002-10-23 루드빅 인스티튜트 포 캔서 리서치 혈관 내피 성장인자 ｄ를 발현하는 암의 치료, 스크리닝,및 검출 방법
US6769080B2 (en) * 2000-03-09 2004-07-27 Texas Instruments Incorporated Scan circuit low power adapter with counter
JP2003527441A (ja) 2000-03-22 2003-09-16 グラクソ グループ リミテッド 細胞周期を阻止する薬剤及び抗体を含む医薬
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001259195A1 (en) 2000-04-28 2001-11-12 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
CA2407970A1 (en) 2000-05-03 2001-11-08 Ludwig Institute For Cancer Research A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
KR100457350B1 (ko) 2000-06-01 2004-11-16 이경림 ＩｇＥ-의존적 히스타민 방출인자(ＨＲＦ)의 수용체,ＨＲＦ 결합 펩타이드 및 그들을 코딩하는 핵산, 및그들의 용도
EP1166799A1 (en) 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
KR20080068151A (ko) 2000-06-23 2008-07-22 바이엘 쉐링 파마 악티엔게젤샤프트 ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
EP1166798A1 (en) 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
AU2001276934A1 (en) 2000-07-18 2002-02-05 Joslin Diabetes Center Inc. Methods of modulating fibrosis
US20020091082A1 (en) 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
FR2814744B1 (fr) 2000-10-04 2002-11-29 Commissariat Energie Atomique Cyclopeptides, leur procede de preparation et leur utilisation comme inhibiteur ou activateur de l'angiogenese
US20030082103A1 (en) 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
AU2002248372B8 (en) 2001-01-19 2008-03-20 Vegenics Limited FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US20030176674A1 (en) 2001-04-13 2003-09-18 Rosen Craig A. Vascular endothelial growth factor 2
JP2005518185A (ja) * 2001-06-04 2005-06-23 キュラジェン コーポレイション 新規タンパク質およびそれをコード化する核酸
CA2450921A1 (en) * 2001-06-22 2003-01-03 Incyte Genomics, Inc. Protein modification and maintenance molecules
WO2003028643A2 (en) 2001-10-01 2003-04-10 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US6766860B2 (en) * 2002-02-22 2004-07-27 Globalsantafe Corporation Multi-activity offshore drilling facility having a support for tubular string
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
CA2483142A1 (en) 2002-05-06 2003-11-20 Genentech, Inc. Use of vegf for treating bone defects
SI2949658T1 (sl) * 2003-03-03 2018-10-30 Dyax Corp. Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe
CA2947346C (en) * 2005-12-09 2018-07-24 Bracco Suisse Sa Targeting vector-phospholipid conjugates
EP2602623B1 (en) * 2008-02-25 2015-09-16 Nestec S.A. Mehtod for the detection of intracellular truncated receptors
US9801473B2 (en) 2012-09-13 2017-10-31 Kids Ii, Inc. Play yard with removable liner
WO2015005839A1 (en) 2013-07-12 2015-01-15 Telefonaktiebolaget L M Ericsson (Publ) Method for enabling control of data packet flows belonging to different access technologies

Also Published As

Publication number Publication date
CA2517939C (en) 2015-11-24
EP1944312B1 (en) 2012-06-27
AU2004217894B2 (en) 2010-07-15
EP1603935A2 (en) 2005-12-14
EP2284180B1 (en) 2015-09-09
JP2011037872A (ja) 2011-02-24
US20050214859A1 (en) 2005-09-29
EP2949658B1 (en) 2018-08-08
WO2004078778A3 (en) 2004-11-18
DK2949658T3 (en) 2018-10-01
JP2007524598A (ja) 2007-08-30
EP2284180A3 (en) 2011-10-05
US9000124B2 (en) 2015-04-07
EP2284180A2 (en) 2011-02-16
DK2284180T3 (en) 2015-12-21
EP1944312A1 (en) 2008-07-16
EP2949658A3 (en) 2016-01-13
CA2517939A1 (en) 2004-09-16
PL1944312T3 (pl) 2012-12-31
US20100261875A1 (en) 2010-10-14
US20120039802A1 (en) 2012-02-16
WO2004078778A2 (en) 2004-09-16
CY1120683T1 (el) 2019-12-11
JP2017019787A (ja) 2017-01-26
ES2692166T3 (es) 2018-11-30
AU2010235865A1 (en) 2010-11-11
HUE039154T2 (hu) 2018-12-28
JP5876644B2 (ja) 2016-03-02
JP6374913B2 (ja) 2018-08-15
EP2949658A2 (en) 2015-12-02
PL2949658T3 (pl) 2018-11-30
ES2557286T3 (es) 2016-01-25
JP5466350B2 (ja) 2014-04-09
ES2396368T3 (es) 2013-02-21
AU2010235865B2 (en) 2012-11-15
JP2014159434A (ja) 2014-09-04
JP6216280B2 (ja) 2017-10-18
US8044175B2 (en) 2011-10-25
AU2004217894A1 (en) 2004-09-16
US20110311446A1 (en) 2011-12-22
US9845340B2 (en) 2017-12-19
US20100260672A1 (en) 2010-10-14
US20150218218A1 (en) 2015-08-06
PT2949658T (pt) 2018-10-18
EP1603935A4 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
HUE039154T2 (hu) HGF receptort (cMet) specifikusan kötõ peptidek és alkalmazásaik
IL183353A0 (en) Polypeptides that bind br3 and uses thereof
EP1636334A4 (en) RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF
EP1613273A4 (en) RECOMBINANT IL-9 ANTIBODIES AND THEIR USE
IL200404A0 (en) 191P4D12(b) PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME; ANTIBODIES BINDING THERETO AND USES THEREOF
AP2007003890A0 (en) Antibodies directed against amy-loid-beta peptide and methods using same
IL179093A0 (en) Anti-il-13 antibodies and complexes
ZA200700895B (en) Polypeptide
IL172510A0 (en) Antibodies and uses thereof
AU2003288809A8 (en) Peptides that bind of the vegfr-2
EP1614695A4 (en) POLYPEPTIDE
IL156263A0 (en) Livin-derived peptides, compositions and uses thereof
AU2003285892A8 (en) Bace binding peptides and uses thereof
GB0309064D0 (en) Modified peptides and their uses
HK1085135A (en) Peptides that specifically bind hgf receptor (cmet) and uses thereof
GB0415196D0 (en) Polypeptide
GB0402904D0 (en) Polypeptide
EP1699809A4 (en) PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF
GB0401303D0 (en) Polypeptide and uses thereof
GB0312990D0 (en) Peptides and uses thereof
GB0323193D0 (en) Peptides and uses thereof
GB0425731D0 (en) Isolated peptides and uses thereof
GB0321401D0 (en) Antibodies,polypeptides and uses thereof
GB0422110D0 (en) Recombinant proteins
IL149179A0 (en) FcyRII-BINDING PEPTIDES AND USES THEREOF